Artificial Intelligence (AI) in Precision Medicine Market Report 2025

The artificial intelligence (AI) in precision medicine market size has grown exponentially in recent years. It will grow from $2.33 billion in 2024 to $3 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%. The growth in the historic period can be attributed to increasing healthcare data availability, rising chronic disease burden, genomic research advancements, growing emphasis on personalized medicine, and improved computational power.

The artificial intelligence (AI) in precision medicine market size is expected to see exponential growth in the next few years. It will grow to $9.18 billion in 2029 at a compound annual growth rate (CAGR) of 32.2%. The growth in the forecast period can be attributed to the expansion of precision medicine initiatives, rising demand for predictive analytics in healthcare, growth in genomics-based therapies, and increased funding for AI in precision medicine research. Major trends in the forecast period include AI-driven biomarker discovery, increased use of natural language processing in healthcare, enhanced patient stratification through AI, AI-enabled clinical trial optimization, and personalized treatment plans using AI-based decision support systems.

The high prevalence of chronic illnesses and respiratory disorders is anticipated to drive the growth of artificial intelligence in the precision medicine market in the future. Chronic illnesses are defined as medical conditions lasting more than a year that require ongoing medical care, while respiratory disorders involve diseases affecting the airways and lungs. Artificial intelligence in precision medicine aids in diagnosing and predicting outcomes for individuals with respiratory diseases by analyzing clinical data and chest imaging. It is utilized in managing chronic illnesses to reduce costs and optimize resource use. For example, in May 2023, the United Nations, a US-based intergovernmental organization, projected that chronic diseases like cardiovascular diseases, cancer, diabetes, and respiratory illnesses would account for 86% of the 90 million deaths expected by 2050. Furthermore, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that the death rate linked to chronic conditions rose from 459 deaths per 100,000 people in 2021 to 490 deaths per 100,000 people in 2022. Consequently, the high prevalence of chronic illnesses and respiratory diseases will drive the growth of artificial intelligence in the precision medicine market.

The artificial intelligence (AI) in precision medicine market is set to grow further due to the escalating demand for personalized medicine. Personalized medicine, leveraging knowledge about an individual's genes or proteins, is gaining traction. AI in precision medicine analyzes molecular data, identifying potential drug targets, predicting drug efficacy, and anticipating side effects, leading to the development of more personalized and effective medications. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting around 34% of all newly approved therapeutic molecular entities, showcasing the rising demand for personalized medicine and its impact on the artificial intelligence in precision medicine market.

A key trend in the artificial intelligence in precision medicine market is the development of innovative AI-based life sciences solutions. Major companies in the market are advancing big data analytics to maintain their competitive edge. For instance, Google LLC introduced a novel AI-based life sciences solution in May 2023, aiming to accelerate drug discovery and precision medicine. The target and lead identification suite enhance in silico drug development by predicting protein structure and precisely determining amino acid function, showcasing the significance of technological advancements in driving market trends.

Strategic collaboration is a focal point for major companies in the artificial intelligence in precision medicine market to sustain their positions. This involves cooperative agreements between entities, such as pharmaceutical and technology companies, with mutual goals. For example, GSK plc and Tempus announced a three-year collaboration agreement in October 2022. GSK gains access to Tempus' AI-enabled platform, utilizing artificial intelligence and machine learning capabilities to enhance clinical trial design, expedite patient enrollment, and identify drug targets. The collaboration aims to improve the efficiency and effectiveness of GSK's research and development processes, particularly in the context of precision medicine, emphasizing the vital role of AI in driving advancements.

In January 2022, Exscientia, a UK-based biotechnology firm specializing in AI-driven drug discovery, entered into a partnership with Sanofi. This collaboration aims to harness advanced AI technologies to revolutionize drug discovery and development processes. Together, Exscientia and Sanofi intend to create up to 15 novel small molecule candidates specifically targeting oncology and immunology, thereby improving the precision and effectiveness of treatments. Sanofi is a France-based pharmaceutical company focused on developing innovative therapies and vaccines to tackle various health challenges, including chronic and rare diseases.

Major companies operating in the artificial intelligence (AI) in precision medicine market include Alphabet Inc., Microsoft Corporation, Intel Corporation, International Business Machines Corporation, AstraZeneca PLC, Sanofi S.A., NVIDIA Corporation, GE HealthCare Technologies Inc., Illumina Inc., QIAGEN N.V., Helix Inc., Sema4 Holdings Corp., SOPHiA GENETICS SA, Insilico Medicine, BenevolentAI Limited, Fabric Genomics Inc., Tempus Technologies Inc., Enlitic Inc., PathAI Inc., Genuity Science Inc., BERG LLC, Perthera Inc., Vuno Inc., CureMetrix Inc., AITIA International Inc., Zephyr AI, Freenome Inc., PetaGene Ltd., Suki AI Inc., BioXcel Therapeutics Inc.

North America was the largest region in the artificial intelligence (AI) in precision medicine market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (ai) in precision medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (ai) in precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

In precision medicine, artificial intelligence involves leveraging advanced computation and inference to generate insights, enabling systems to reason, learn, and assist healthcare professionals in decision-making through augmented intelligence. Its application in precision medicine aims to optimize diagnosis, therapeutic intervention, and prognosis within the healthcare sector.

The primary components of artificial intelligence (AI) in precision medicine encompass hardware, software, and services. Hardware pertains to the physical components of a system or the mechanisms involved in storing and executing the instructions embedded in the application's software. Various technologies, such as deep learning, querying methods, natural language processing, and context-aware processing, are employed in diverse therapeutic applications, including oncology, cardiology, neurology, respiratory, and others.

The artificial intelligence (AI) in precision medicine market research report is one of a series of new reports that provides artificial intelligence (AI) in precision medicine market statistics, including the artificial intelligence (AI) in precision medicine industry's global market size, regional shares, competitors with artificial intelligence (AI) in precision medicine market share, detailed artificial intelligence (AI) in precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in precision medicine industry. This artificial intelligence (AI) in precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The artificial intelligence in the precision medicine market consists of revenues earned by entities providing artificial intelligence in precision medicine services that include personalized treatment, disease prevention, and personalized diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence in the precision medicine market also includes sales of wearable devices, implantable devices, and artificial intelligence devices in precision medicine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.